Here’s Why GlaxoSmithKline plc Is Set To Outperform Unilever plc & Diageo PLC

GlaxoSmithKline plc (LON:GSK), Diageo PLC (LON:ULVR) and Diageo PLC (LON:DGE) are under the spotlight.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

On 6 May we attended the consumer part of GSK’s investor event, hosted by Emma Walmesley, CEO of GSK Consumer Healthcare,” analysts at Royal Bank of Canada wrote in research published today, adding that “in many respects it was just like any other consumer company presentation.”

Consumer healthcare generates about 20% of GlaxoSmithKline‘s (LSE: GSK) revenues, and marginally contributes to its valuation, which  is more appealing than that of consumer staples such as Unilever (LSE: ULVR) and Diageo (LSE: DGE), I’d argue. Here’s why.

Glaxo

Glaxo is more profitable than Unilever, with forward operating margins expected to be in mid-20s into 2016. And whilst it’s less profitable than Diageo, it’s financially stronger. 

Revenues are unlikely to grow much, and that’s not too different an outlook from that of Diageo and Unilever.

Glaxo’s forward yield is forecast to hover around 5%–5.5% between 2015 and 2017 — and such forecasts are accurate, in my view. At 21x and 11x forward earnings and adjusted operating cash flow, respectively, its stock could be considered as part of a diversified portfolio, although its earnings per share could come come under pressure this year.

The stock is up 4% so far in 2015, but has lost 12% of value over the last month, as analysts have become more bearish about its short-term earnings prospects. If you are after long-term value, there’s little you should worry about at this price, however. 

Finally it has long been debated whether Glaxo should hold less cyclical consumer assets, and upside could certainly come from spin-offs. Investors are nervous, though, and a change of management would benefit Glaxo’s own valuation. 

Unilever

Unilever’s forward operating margins are expected to be in the range of 15% this year and next. Revenues may grow at a faster pace than at Glaxo and Unilever, but the price to pay for a steeper growth rate is a lower forward yield, in the region of 3%, although that is based on sustainable cash flows.

At 21x and 14x forward earnings and adjusted operating cash flow, respectively, Unilever is less attractive than Glaxo, but is a more promising investment than Diageo, based on the conditions of its end markets and the lower level of cyclicality of its core products.  

Unilever’s shares have risen 11% in 2015, but they are down 2% in the last month of trading. One element to consider is that with Unilever you’d likely add less risk to your portfolio than with Glaxo. 

Diageo 

Diageo’s forward operating margins are expected to be very close to 30% in the next couple of years, but I am concerned about its growth rate for revenues, which will likely be a drag both on margins and on its equity valuation. 

A generous dividend policy and relatively high leverage render Diageo a less appealing investment than Glaxo and Unilever. Its shares have lost 2% of value this year, and about 4% in the last four weeks. 

At 3%, its forward yield also signals risk rather than an enticing yield opportunity, based on fundamentals. 

At 21x and 15x forward earnings and adjusted operating cash flow, Diageo is less attractive than Glaxo and Unilever, unless it manages to grow at a faster pace via acquisitions — but that, in turn, would heighten the its risk profile. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Down 5%, Glencore’s share price looks a serious bargain to me now

Glencore’s share price looks undervalued to me, supported by strong earnings growth prospects and the potential resumption of extra shareholder…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’d invest £6,580 in this FTSE 250 REIT for £500 passive income

This FTSE 250 renewable energy enterprise is on track to become a Dividend Aristocrat! Here’s how I’d invest to earn…

Read more »

Investing Articles

Buying 1,000 of some dividend shares today unlocks £45 in weekly passive income!

These shares are among the biggest dividend payers in the FTSE 100. Should investors be buying them now to earn…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

If I’d put £5k in index funds 5 years ago, here’s what I’d have now

Investing in index funds is an excellent way to grow wealth with minimal effort. But how much money can investors…

Read more »

Investing Articles

10.2% yield! 1 of the top income stocks to buy in July?

A 10% yield's pretty rare, but this firm's been growing shareholder payouts for nine years! Does that make it one…

Read more »

Investing Articles

‘FTSE 100 to skyrocket to 10,000’! 1 cheap stock I’d buy before the surge

Analyst forecasts predict a massive surge for the FTSE 100 may be coming by April 2025! Should investors snap up…

Read more »

Investing Articles

My Taylor Wimpey share price prediction for the second half of 2024

Having underperformed the FTSE 100 from January to June, our writer reckons the Taylor Wimpey share price might enjoy a…

Read more »

Investing Articles

£10k in savings? Here’s how I’d aim to turn it into a £4,894 annual passive income with Aviva shares

Aviva might be one of the FTSE 100's hottest dividend shares right now. I'm banking on it to provide me…

Read more »